News >

Pomalidomide Triplet Improves PFS in Relapsed/Refractory Myeloma

Jason M. Broderick @jasoncology
Published: Tuesday, Feb 06, 2018

 Paul Richardson, MD

Paul Richardson, MD
Adding pomalidomide (Pomalyst) to the combination of bortezomib (Velcade) and low-dose dexamethasone (PVd) led to a significant improvement in progression-free survival (PFS) in patients with relapsed/refractory myeloma with prior exposure to lenalidomide (Revlimid), according to findings from the phase III OPTIMISMM trial.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication
x